Under the agreement, SynCo will fill and finish batches of OncoMed’s lead product, antibody OMP-21M18, for use in Phase I clinical trials. SynCo will fill and finish antibody at its Amsterdam-based facility. This facility is able to fill a wide range of biopharmaceuticals into vials, including protein, polysaccharide, and live-microbial-based products using the latest filling and finishing equipment.
Paul Hastings, president and CEO of OncoMed, said: “We selected SynCo Bio Partners because we needed a GMP-accredited contract manufacturing organization that had a proven track record in filling biologics. With SynCo’s expertise in all aspects of biopharmaceutical manufacture, they were an ideal partner for us at this crucial stage in our development.”